mitomycin and Prosthesis Durability

mitomycin has been researched along with Prosthesis Durability in 6 studies

Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.

Research

Studies (6)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Number of Participants With Postoperative Complications Between Targeted Supratenon's Placement of XEN-45 Gelatin Stent and Non-targeted Placement.

"Presence or absence of the following complications:~i. Starting after POM1: shallow AC w/ iridocorneal touch, any hyphema, corneal edema, wound leak/dehiscience, choroidal effusion, malignant glaucoma, dellen/non-healing epithelial defect, ptosis, diplopia.~ii. At any point: additional glaucoma surgery, loss of light perception vision, vitreous hemorrhage, ≥2mm hyphema, hypotony maculopathy, implant migration/blockage/exposure/extrusion, macular edema, choroidal effusion/hemorrhage requiring drainage, suprachoroidal hemorrhage, retinal detachment, suture abscess/blebitis/endophthalmitis" (NCT04454138)
Timeframe: Post op year 1

Number of Participants With Postoperative Interventions Between Targeted Supratenon's Placement of XEN-45 Gelatin Stent and Non-targeted Placement.

Presence or absence of the following management interventions (not considered complications): bleb needling, AC reformation, suture release, digital ocular compression, use of glaucoma medications, or laser/tpa to blocked ostomy or lumen. (NCT04454138)
Timeframe: Post op year 1

Postoperative Intraocular Pressure Changes Between Targeted Supratenon's Placement of XEN-45 Gelatin Stent and Nontargeted Placement 2.

Mean change in IOP from baseline, IOP thresholds of ≥6 and ≤14 (mmHg) +/- Medications (NCT04454138)
Timeframe: Post op Year 1

Postoperative Intraocular Pressure Changes Between Targeted Supratenon's Placement of XEN-45 Gelatin Stent and Nontargeted Placement 3.

Mean change in IOP from baseline, IOP thresholds of ≥6 and ≤17 (mmHg) on no medications (NCT04454138)
Timeframe: Post op year 1

Postoperative Intraocular Pressure Changes Between Targeted Supratenon's Placement of XEN-45 Gelatin Stent and Nontargeted Placement 4.

Mean change in IOP from baseline, IOP thresholds of ≥6 and ≤17 (mmHg) +/- medication (NCT04454138)
Timeframe: Post op Year 1

Postoperative Intraocular Pressure Changes Between Targeted Supratenon's Placement of XEN-45 Gelatin Stent and Nontargeted Placement 5.

Mean change in IOP from baseline, IOP thresholds of ≥6 and ≤21 (mmHg) on no medications (NCT04454138)
Timeframe: Post op Year 1

Postoperative Intraocular Pressure Changes Between Targeted Supratenon's Placement of XEN-45 Gelatin Stent and Nontargeted Placement 6.

Mean change in IOP from baseline, IOP thresholds of ≥6 and ≤14 (mmHg) +/- medications (NCT04454138)
Timeframe: Post op year 1

Postoperative Intraocular Pressure Changes Between Targeted Supratenon's Placement of XEN-45 Gelatin Stent and Nontargeted Placement.

Mean change in IOP from baseline, IOP thresholds of ≥6 and ≤14 (mmHg) on no medications (NCT04454138)
Timeframe: Post op year 1

Other Studies

6 other studies available for mitomycin and Prosthesis Durability